DOT1L and acute myeloid leukemia: While initial clinical trials of DOT1L inhibitors reported limited success, preclinical work reveals that pinometostat may enhance the sensitivity of pediatric AML cells to the multikinase inhibitor sorafenib, suggesting a new avenue for treatment protocols, potentially reshaping the therapeutic landscape for pediatric AML.252